Earnings call transcript: Research Solutions posts higher margins in Q4 2026

Research Solutions reported fiscal 2026 revenue of $48.3 million, down 1.6%, but net income more than doubled to $2.8 million and gross margin expanded 260bps to 51.9% as higher-margin platform subscriptions grew 10%. ARR increased 7.8% to $22.5 million, including $800,000 of AI-related ARR versus near zero a year earlier, while transaction revenue declined 8.7%. Management expects further EBITDA and cash-flow improvement in fiscal 2027, supported by AI product scaling and B2B growth, but did not issue formal guidance and expects continuing low-single-digit declines in legacy transaction revenue.

Analysis

RSSS is becoming a mix-shift story rather than a clean AI-growth story: recurring platform economics can lift consolidated margins even if reported revenue remains flat-to-down, but the valuation re-rate requires proof that AI is additive rather than simply cannibalizing legacy search and document-delivery workflows. The critical underwriting issue is concentration: AI-related ARR appears to account for a substantial portion of recent net B2B ARR growth, yet management does not disclose new-logo versus renewal repricing, attach rate, churn, or pipeline conversion. Until that disclosure arrives, investors should not capitalize early AI usage at a SaaS-like multiple.

The most valuable strategic asset may be rights-cleared access and publisher relationships, not the connector itself. Large-model vendors can commoditize search and interface layers, while publisher-side entitlement, billing, auditability, and indemnification create potential switching costs. Conversely, publishers could build direct AI licensing rails or route through larger incumbents such as RELX (RELX), Wiley (WLY), Springer Nature (SPGGF), or Clarivate (CLVT), limiting RSSS's take rate before the network effect becomes durable.

Near term, the setup is a small-cap liquidity/event trade, not a high-conviction fundamental catalyst: an authorization or execution of repurchases could support the stock, but remaining acquisition-related obligations and lower operating cash conversion constrain the signal value of cash. Over the next 1-3 months, Q1 renewal performance, net B2B ARR, AI revenue disclosure, and transaction-revenue deceleration determine whether the market treats the margin expansion as durable. Over 6-18 months, sustained platform growth and publisher-gateway adoption could justify a rerating; failure to return total revenue to growth would instead expose operating leverage and keep the shares range-bound.

Contrarian view: the market may be underpricing the possibility that agentic workflows increase paid content consumption rather than destroy it, particularly in regulated pharma and corporate R&D where provenance matters. But management's usage claims are not equivalent to monetization; the thesis is falsified if AI ARR stalls, retention gains fail to translate into net revenue retention, or transaction declines reaccelerate despite broader AI adoption.

Key Decisions for Investors

• Watch, do not initiate at market: RSSS lacks formal revenue guidance and sufficient AI monetization disclosure. Reassess after the next quarterly report only if net B2B ARR growth accelerates, AI revenue is separately disclosed, and total revenue decline narrows materially; otherwise treat margin gains as mix-driven rather than growth-driven.
• For a small-cap/event sleeve, consider a limited long RSSS position only on confirmation of an executed repurchase program, not a stated evaluation. Size for liquidity risk and target a 6-12 month horizon; exit if cash falls materially after earn-out payments without corresponding ARR acceleration or if transaction revenue returns to high-single-digit declines.
• Monitor RELX, WLY, CLVT and SPGGF as the better-capitalized publisher/data proxies for enterprise AI research monetization. Favor them over RSSS if publisher AI-rights announcements begin to bypass intermediary gateways, which would weaken RSSS's proposed network-effect moat.
• Set an operational alert for the next earnings release: a combination of improving renewal/upsell metrics, stable customer count, and AI growth beyond existing-account repricing would validate a rerating case. Evidence that MCP usage substitutes for paid core-product usage without higher contract value invalidates the long thesis.